C3 and acute myeloid leukemia: For the AML patients with True response status, the abundance of UBE2N+NK-C1, PARK7+NK-C4, and TUBA1A+Mac-C3 was higher, while the abundance of DYNC1H1+CD8+ T−C2 was lower (Figure 6A).